Gyre Therapeutics MACD Death Cross and Bearish Marubozu Signal Decline

Gyre Therapeutics' 15-minute chart has recently triggered a MACD Death Cross and a Bearish Marubozu at 06/23/2025 11:45. This indicates that the stock price has the potential to continue declining, with sellers dominating the market, and a bearish momentum that is likely to persist.

Gyre Therapeutics, Inc. (NASDAQ: GYRE) experienced a significant drop in its stock price on June 23, 2025, at 11:45 AM, with the 15-minute chart triggering a MACD Death Cross and a Bearish Marubozu. These technical indicators suggest that the stock price is likely to continue declining, with sellers dominating the market and a persistent bearish momentum.

The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a potential change in the stock's trend from bullish to bearish. The Bearish Marubozu, characterized by a long white candle with no wicks, further reinforces this bearish signal. Both indicators suggest that the current selling pressure is strong and likely to continue.

The stock price, which had previously closed at $8.03, traded as high as $8.41 and last traded at $8.35 on June 23, 2025. The volume of shares traded was 30,546, a decline of 75% from the average session volume of 123,283 shares. This significant drop in volume indicates a lack of buying interest and further supports the bearish trend.

Analysts have been cautious about Gyre Therapeutics. While Noble Financial began coverage on the stock on March 11, 2025, and issued an "outperform" rating, the stock has since faced challenges. The company reported an earnings per share (EPS) of $0.03 for the quarter ending May 9, 2025, which met analysts' consensus estimates but fell short of revenue expectations.

Institutional investors have also been active in Gyre Therapeutics. Bank of New York Mellon Corp, SBI Securities Co. Ltd, Charles Schwab Investment Management Inc., Wells Fargo & Company MN, and Barclays PLC have all increased their stakes in the company in the fourth quarter of 2024. However, the recent decline in the stock price suggests that these investors may be reassessing their positions.

Gyre Therapeutics focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MAS) and liver fibrosis. Despite its promising pipeline, the stock has faced headwinds, including regulatory challenges and competition from other biopharmaceutical companies.

Investors should closely monitor Gyre Therapeutics' stock price and any upcoming earnings reports or news announcements. The recent technical signals suggest a potential decline in the stock price, and investors should be prepared for volatility in the near term.

References:
[1] https://www.marketbeat.com/instant-alerts/gyre-therapeutics-nasdaqgyre-trading-up-4-heres-what-happened-2025-06-17/